Nature, The Best Chemist | Dr. Siyaram Pandey

Videos For An Earth In Transition – http://www.earth-heal.com/index.php/videos.html  

Source: TEDx Talks 

Despite tremendous advancement in the knowledge of cancer development over past decades, it still remains a challenge to treat. Other than surgery, most available treatment (radiation and chemotherapy) are nonselective, i.e. they are unable to distinguish cancer verses healthy cells, and saddled with toxic side effects. These harsh side effects include compromised immunity, and increased chances of reoccurrence of cancer. Natural health products (NHPs) or natural extracts play a leading role in the discovery and the development of drugs for the treatment of human diseases. Traditional medicines in the Native American, Chinese, and Indian cultures have utilized numerous natural products, including dozens of spices and plant extracts. In fact, more than 50% of current cancer therapeutics are derived from various natural extracts. However, the efficacy of natural extracts as complex mixtures (unpurified, as used traditionally) in treating cancer has not been explored extensively.

Siyaram Pandey is a Professor in the Department of Chemistry & Biochemistry at the University of Windsor. He received his MSc from Banaras Hindu University (1986), Varansi, India and his PhD from Jawaharlal Nehru University/CCMB (1992), New Delhi, India. He did is postdoctoral training at McGill and joined NRC, Ottawa as a research officer (1993-2000). He joined the University of Windsor in 2000. Dr. Pandey’s research is focused on apoptosis (cell suicide), which is central to various aspects of human health including neurodegeneration, stroke and cancer. He is currently the President of the Natural Health Product Research Society of Canada. He is also currently the Founder Director and Chief Scientific Officer of the Windsor Botanical Therapeutics Inc. Toronto. His group is known for their discovery of the novel natural anti-cancer compound Pancratistatin, and Dandelion Root extract which is in clinical trial for blood cancer.